B-cell receptor specific for HIV-1 envelope glycoprotein 120 (gp120) epitopes (HIV-1 gp120-specific BCR)

B-cell receptors (BCRs) specific for HIV-1 envelope glycoprotein 120 (gp120) epitopes are the primary immunological targets for germline-targeting HIV-1 vaccines (IAVI, 2022). These receptors, located on the surface of B lymphocytes, are responsible for the initial recognition of the HIV-1 envelope spike, specifically the gp120 subunit which mediates viral attachment to host CD4+ T cells (NIH, 2024). In vaccine design, these BCRs are targeted to activate specific B-cell lineages, such as those expressing the VH1-2*02 germline allele, which have the potential to mature into broadly neutralizing antibodies (bNAbs) like VRC01 (Science, 2022). By utilizing engineered immunogens that bind with high affinity to these precursor BCRs, researchers aim to overcome the challenges of HIV's high sequence diversity and glycan shielding (PubMed, 2023). The interaction between vaccine immunogens and these BCRs triggers B-cell activation, proliferation, and entry into germinal centers for affinity maturation (Nature, 2024). This process is critical for the development of a protective immune response capable of neutralizing a wide array of global HIV-1 strains. Clinical candidates like eOD-GT8 60mer and various mRNA-based gp120 vaccines are designed to specifically engage these BCRs to prime the immune system for subsequent booster shots (IAVI, 2022). Success in targeting these receptors is measured by the expansion of epitope-specific B cells and the eventual production of high-titer neutralizing antibodies in the serum (Science, 2023).

Other names

HIV-1 gp120-specific B-cell receptorAnti-gp120 BCRgp120-reactive B-cell receptorVRC01-class B-cell receptor precursorGermline-targeting BCR

Vaccine-mediated engagement of germline B-cell receptors to induce activation, clonal expansion, and affinity maturation toward broadly neutralizing antibody (bNAb) phenotypes.